Mjust
$TYRA strong cash position, but a few things worth examining.
TYRA reported approximately $700.5M in cash and marketable securities after raising $400M in September.
What caught my attention:
• All 9.08M pre-funded warrants issued in the September financing went to an existing shareholder affiliated with a board member.
• Q3 R&D expenses increased approximately 69% year over year, from $25.5M to $43.1M.
• The company still faces significant clinical execution risk, with its valuation dependent on future trial results.
The cash runway looks strong, but cash alone doesn’t guarantee clinical or commercial success.
Interested in how management balances spending, shareholder dilution, and clinical milestones.
